NCT02275910 - Phase 1 Study of E7090 in Subjects With Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions

Tumors

Interventions

DRUG

E7090

Trial Locations (18)

Eisai Trial Site #1, Nagoya

Eisai Trial Site #1, Kashiwa

Eisai Trial Site #1, Matsuyama

Eisai Trial Site #1, Sapporo

Eisai Trial Site #1, Amagasaki

Eisai Trial Site #1, Tsukuba

Eisai Trial Site #1, Kawasaki

Eisai Trial Site #1, Yokohama

Eisai Trial Site #1, Chuo-ku

Eisai Trial Site #1, Kitaadachi

Eisai Trial Site #1, Chuo-Ku

Eisai Trial Site #1, Koto-ku

Eisai Trial Site #1, Chiba

Eisai Trial Site #1, Fukuoka

Eisai Trial Site #1, Kyoto

Eisai Trial Site #1, Osaka

Eisai Trial Site #2, Osaka

Eisai Trial Site #3, Osaka

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY